Publicité
English Flag
Biotech Finances - L'information stratégique des biodécideurs et des bioinvestisseurs
RECHERCHER SUR LE SITE
ET DANS LES ARCHIVES
mardi 21 octobre 2014
 Mmoriser  
 
 

Communiqu de Presse

Natera to Present Update About Development, Commercialization of Non-Invasive Prenatal Diagnostic Test at the Citi 2012 Global Health Care Conference

Le 24/02/2012 14:02

Logo
Feb. 24, 2012 13:00 UTC

Natera to Present Update About Development, Commercialization of Non-Invasive Prenatal Diagnostic Test at the Citi 2012 Global Health Care Conference

Citi Global Health Care Conference 2012

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Natera, formerly known as Gene Security Network, today announced that the company is scheduled to present at the Citi 2012 Global Health Care Conference at 4 p.m. EST on Monday, February 27, 2012, at the Waldorf Astoria in New York City. Matthew Rabinowitz, Ph.D., Natera's chief executive officer, will provide an overview of the company and an update on its reproductive genetic testing services.

"Our non-invasive prenatal diagnostic test is moving rapidly through development, including an NIH-funded clinical investigation, toward global commercialization later this year," said Rabinowitz. "We look forward to presenting at this conference and providing background about how our test will be able to deliver highly accurate results for detection of multiple conditions, including trisomy 13, 18 and 21, as well as certain sex chromosome abnormalities."

About Natera

Natera is a genetic testing company that has developed a proprietary bioinformatics technology (Parental Support) to deliver accurate and comprehensive high throughput testing for reproductive indications from tiny quantities of DNA ? as small as that from a single cell. Natera operates a CLIA laboratory in Redwood City, Calif., providing a host of reproductive genetic testing services. Test offerings include preimplantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an IVF cycle in order to select embryos with the highest probability of becoming healthy children; products of conception testing following miscarriage to rapidly and extensively analyze fetal chromosomes in order to understand the cause; and non-invasive prenatal testing to determine paternity or detect genetic disease by analyzing fragments of fetal DNA in a pregnant mother's blood drawn in the first trimester. Non-invasive testing for paternity is currently available worldwide. Natera's clinical trial for non-invasive detection of chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. For more information, visit www.natera.com.

Contacts

Russo Partners
Ian Stone, 619-308-6540
ian.stone@russopartnersllc.com
Lena Evans, 212-845-4262
lena.evans@russopartnersllc.com
or
Natera, Inc.
Jennifer Keller, 650-249-9090 ext. 309
jkeller@natera.com


Source: Natera